. Author manuscript; available in PMC: 2017 Jun 1.

Published in final edited form as: Lancet Respir Med. 2016 Oct 20;4(12):980–989. doi: 10.1016/S2213-2600(16)30319-8

Table 4.

Effect of immediate versus deferred antiretroviral therapy (ART) initiation on bronchitis episodes

	Immediate ART		Deferred ART		p value^*
	n	Number (%) who had a bronchitis event	n	Number (%) who had a bronchitis event
Smokers

Baseline	135	49 (36%)	155	54 (35%)
Year 1	117	34 (29%)	126	37 (29%)	1·00
Year 2	96	27 (28%)	110	24 (22%)	0·33
Year 3	58	11 (19%)	65	10 (15%)	0·64
Year 4	24	8 (33%)	22	2 (9%)	0·07

Non-smokers

Baseline	383	96 (25%)	353	76 (22%)
Year 1	339	62 (18%)	302	55 (18%)	1·00
Year 2	295	45 (15%)	265	37 (14%)	072
Year 3	130	20 (15%)	120	17 (14%)	0·86
Year 4	42	11 (26%)	29	4 (14%)	025

Effects grouped by treatment and smoking status. Odds ratio from Generalised Estimating Equation with outcome as having any episodes of bronchitis at each follow-up visit: for smokers 1·16 (95% CI 0·66–2·02, p=0·61; for non-smokers 0·89 (0·60–1·32), p=0·57

From Fisher’s exact test.